Stockscreener 앱 받기
4.70
3.69%
-0.18
시장 영업 전:
4.70
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
What high frequency data says about Cellectar Biosciences Inc.Index Update & Community Shared Stock Ideas - Newser
Visualizing Cellectar Biosciences Inc. stock with heatmapsTrade Signal Summary & Daily Profit Focused Stock Screening - Newser
What’s next for Cellectar Biosciences Inc. stock priceMarket Sentiment Report & Weekly Momentum Picks - Newser
Using Ichimoku Cloud for Cellectar Biosciences Inc. technicals2025 AllTime Highs & Advanced Swing Trade Entry Alerts - Newser
Does Cellectar Biosciences Inc. show high probability of rebound2025 Trading Volume Trends & High Accuracy Swing Entry Alerts - Newser
Using AI based signals to follow Cellectar Biosciences Inc.2025 Key Lessons & Technical Pattern Based Signals - Newser
Will Cellectar Biosciences Inc. see short term momentumTrade Volume Summary & Weekly Top Gainers Alerts - Newser
XTX Topco Ltd Increases Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Earnings Chart Overlay Points to Cellectar Biosciences Inc. UpsideQuarterly Portfolio Review & Weekly Consistent Profit Watchlists - 선데이타임즈
How high can Cellectar Biosciences Inc. stock go2025 Technical Patterns & Risk Managed Investment Signals - Newser
How sentiment analysis helps forecast Cellectar Biosciences Inc.Recession Risk & Low Drawdown Investment Ideas - Newser
Advanced analytics toolkit walkthrough for Cellectar Biosciences Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - Newser
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - MSN
Support Zone Holds Steady for Cellectar Biosciences Inc. After Dip2025 Winners & Losers & Daily Entry Point Trade Alerts - 선데이타임즈
Key metrics from Cellectar Biosciences Inc.’s quarterly dataWeekly Profit Recap & Verified High Yield Trade Plans - Newser
Oppenheimer Maintains Hold Rating on Cellectar Biosciences with $18.00 Average Price Target - AInvest
Cellectar Cuts Q2 Losses and Expenses - AOL.com
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2025 Earnings Call Transcript - MSN
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Cellectar signals NDA submission for iopofosine I-131 in WM by early 2026 amid accelerated approval focus - MSN
Cellectar Biosciences Reports Q2 2025 Financial Results - TipRanks
Cellectar Biosciences Reports Q2 EPS $3.39, Below Consensus $3.70 - AInvest
Cellectar Biosciences Q2 2025 Earnings Report - MarketBeat
Cellectar Biosciences shares fall 1.81% after-hours following Q2 2025 earnings call. - AInvest
Cellectar's 2025 Q2 Earnings Call: Key Contradictions in Phase 3 Trial Strategy and Cost Projections - AInvest
Cellectar to Submit NDA for Iopofosine I-131 in WM by Early 2026, Focuses on Accelerated Approval - AInvest
Earnings call transcript: SelectR Biosciences Q2 2025 reports $5.4M loss - Investing.com
Cellectar Biosciences shares rise 7.47% premarket after reporting positive updates on Iopofosine I 131 and CLR 125. - AInvest
Cellectar Achieves Q2 Loss Reduction, R&D Expenses Drop 67.1% - AInvest
Cellectar Biosciences Reports Q2 GAAP EPS of -$3.39, Beats Estimate by $0.31, with Cash and Cash Equivalents of $11M as of June 30. - AInvest
Cellectar Biosciences Advances Iopofosine I 131 for WM, CLR 125 for TNBC. - AInvest
Cellectar's Blood Cancer Drug Gets FDA Breakthrough Status, Eyes Accelerated Approval Path - Stock Titan
Cellectar Biosciences, Inc. SEC 10-Q Report - TradingView
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionTrade Risk Report & Weekly Top Gainers Trade List - Newser
Cellectar Biosciences Q2 2025 Earnings Preview: Analysts Expect $-3.66 EPS - AInvest
How to manage a losing position in Cellectar Biosciences Inc.Weekly Earnings Recap & Weekly Return Optimization Alerts - Newser
Published on: 2025-08-13 08:37:11 - Newser
Cellectar Biosciences Inc. stock chart pattern explained2025 Market Overview & Long-Term Growth Portfolio Plans - Newser
How to recover losses in Cellectar Biosciences Inc. stockSummary of Trade Cycles in 5-Year Range - Newser
What moving averages say about Cellectar Biosciences Inc.Free Investment Strategy With Low Risk - Newser
Multi factor analysis applied to Cellectar Biosciences Inc.High Return Trade Roadmap with Setup Filters - Newser
Cellectar Biosciences Inc. stock trend forecastTechnical Trend Forecast for Investors - Newser
What recovery options are there for Cellectar Biosciences Inc.Daily Stock Movement Forecast with Accuracy - Newser
Cellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on Thursday - Defense World
A | What is Cellectar Biosciences, Inc.'s revenue forecastBest ROI Stock Strategies - newsyoung.net
Will a bounce in Cellectar Biosciences Inc. offer an exitPattern Recognition Tool for ROI Investors - Newser
Cellectar Biosciences reports Q2 financial results, conference call on August 14. - AInvest
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 - Yahoo Finance
Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc - Barchart.com
Is Cellectar Biosciences Inc. trending in predictive chart modelsFree Smart Money Tracking Signal Generator - Newser
Cellectar Biosciences Inc. Shows Early Signs of Technical StrengthInvestment Plan With Growth Optimization Finalized - metal.it
Is it the right time to buy Cellectar Biosciences Inc. stockInvest in stocks with long-term growth potential - Jammu Links News
When is Cellectar Biosciences Inc. stock expected to show significant growthGet real-time updates on market trends - Jammu Links News
Is Cellectar Biosciences Inc. stock overvalued or undervaluedExtraordinary market timing - Jammu Links News
1.38%
0.27%
자본화:
|
볼륨(24시간):